Publication number: 20250090519
Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(triflu-oromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl] [2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of car-diopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hyperten-sion (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pu
Type:
Application
Filed:
July 22, 2024
Publication date:
March 20, 2025
Inventors:
Eva Maria BECKER-PELSTER, Hanna TINEL, Michael HAHN, Dieter LANG, Gerrit WEIMANN, Johannes NAGELSCHMITZ, Lisa DIETZ, Soundos SALEH, David JUNG, Ildiko TEREBESI, Tobias MUNDRY, Annett RICHTER, Britta OLENIK, Birgit KEIL, Bernd RÖSLER, Peter FEY, Heiko SCHIRMER, Guido BECKER, Clemens BOTHE, Helene FABER, Julian EGGER, Mark PARRY, David WARD, Cecile VITRE